EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Self‐ and study partner–reported cognitive decline in older adults without dementia: The role of α‐synuclein and amyloid biomarkers in the Alzheimer's Disease Neuroimaging Initiative

Kelsey R Thomas, Katherine J Bangen, Lindsay J Rotblatt, Alexandra J Weigand, Lauren Edwards, Duygu Tosun, Douglas Galasko, Alzheimer's Disease Neuroimaging Initiative

Alzheimer's & Dementia · 2024

DOI: 10.1002/alz.14239 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Alzheimer's & Dementia, 2024. Verfasst von Kelsey R Thomas und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Psychiatry, University of California, San Diego, La Jolla, California, USA. Hauptthemen laut MEDLINE: alpha-Synuclein, Biomarkers, Cognitive Dysfunction, Amyloid beta-Peptides. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: CSRD VA, NIA NIH HHS, U.S. Department of Veterans Affairs Clinical Sciences Research and Development Service.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

INTRODUCTION Subjective cognitive decline (SCD) may be an early marker of Alzheimer's disease (AD) pathology. Until recently, it was impossible to measure biomarkers specific for α‐synuclein pathology; therefore, its association with subjective reports of cognitive decline is unknown. METHODS Alzheimer's Disease Neuroimaging Initiative participants without dementia ( n = 918) were classified as positive or negative for amyloid beta (Aβ+ or Aβ−) and α‐synuclein (α‐syn+ or α‐syn−) biomarkers. Self‐ and study partner–reported cognitive decline was measured with the Everyday Cognition (ECog) questionnaire. RESULTS Per self‐report, Aβ+/α‐syn+ had the greatest cognitive decline. Aβ−/α‐syn+ did not differ from Aβ−/α‐syn− across ECog scores. Study partner–reported results had a similar pattern, but Aβ+/α‐syn− and Aβ+/α‐syn+ did not differ across ECog scores. Mild cognitive impairment classification moderated the study partner–reported memory score. DISCUSSION While α‐syn+ alone did not increase subjective reports of cognitive decline, Aβ+/α‐syn+ had the most self‐ and study partner–rated cognitive decline. Therefore, the presence of multiple pathologies was associated with greater SCD. Highlights Cerebrospinal fluid α‐synuclein (α‐syn) seed amplification assay was used to determine α‐syn positivity. Amyloid beta (Aβ)−/α‐syn−, Aβ−/α‐syn+, Aβ+/α‐syn−, and Aβ+/α‐syn+ biomarker groups were created. Aβ+/α‐syn+ had greater subjective cognitive decline (SCD) than the other biomarker groups. Aβ−/α‐syn+ did not differ from Aβ−/α‐syn− across self‐ or study–partner reported SCD scores. Study partner–reported subjective memory results were largely driven by participants with mild cognitive impairment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

alpha-SynucleinBiomarkersCognitive DysfunctionAmyloid beta-PeptidesSelf ReportNeuroimagingHumansFemaleMaleAgedAlzheimer DiseaseAged, 80 and overNeuropsychological Tests

Stichwörter der Autor:innen

Alzheimer's Disease Neuroimaging InitiativeEveryday CognitionLewy body pathologyamyloid betaseed amplification assaysubjective cognitive declineα‐synuclein

Substanzen

alpha-SynucleinBiomarkersAmyloid beta-Peptides

Autor:innen und Institutionen

  • Department of Psychiatry, University of California, San Diego, La Jolla, California, USA.
  • VA San Diego Healthcare System, San Diego, California, USA.
  • San Diego State University/University of California, San Diego Joint Doctoral Program in Clinical Psychology, San Diego, California, USA.
  • Department of Radiology and Biomedical Imaging, University of California, San Francisco, San Francisco, California, USA.
  • Department of Neurosciences, University of California, San Diego, La Jolla, California, USA.

Förderung

  • CSRD VA
  • NIA NIH HHS
  • U.S. Department of Veterans Affairs Clinical Sciences Research and Development Service
  • Alzheimer's Association

Zitieren

APA

Thomas, K. R., Bangen, K. J., Rotblatt, L. J., Weigand, A. J., Edwards, L., Tosun, D., Galasko, D., & Alzheimer's Disease Neuroimaging Initiative (2024). Self‐ and study partner–reported cognitive decline in older adults without dementia: The role of α‐synuclein and amyloid biomarkers in the Alzheimer's Disease Neuroimaging Initiative. Alzheimer's & Dementia. https://doi.org/10.1002/alz.14239

Vancouver

Thomas KR, Bangen KJ, Rotblatt LJ, Weigand AJ, Edwards L, Tosun D, et al. Self‐ and study partner–reported cognitive decline in older adults without dementia: The role of α‐synuclein and amyloid biomarkers in the Alzheimer's Disease Neuroimaging Initiative. Alzheimer's & Dementia. 2024. doi:10.1002/alz.14239

BibTeX
@article{Thomas2024,
  author = {Thomas, Kelsey R and Bangen, Katherine J and Rotblatt, Lindsay J and Weigand, Alexandra J and Edwards, Lauren and Tosun, Duygu and Galasko, Douglas and Alzheimer's Disease Neuroimaging Initiative, Alzheimer's Disease Neuroimaging Initiative},
  title = {Self‐ and study partner–reported cognitive decline in older adults without dementia: The role of α‐synuclein and amyloid biomarkers in the Alzheimer's Disease Neuroimaging Initiative},
  journal = {Alzheimer's & Dementia},
  year = {2024},
  doi = {10.1002/alz.14239}
}
Kostenlos starten →